MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.978
EU - Europa 2.195
AS - Asia 583
OC - Oceania 8
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 2
Totale 6.776
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.953
GB - Regno Unito 1.173
IT - Italia 284
CN - Cina 261
SE - Svezia 205
DE - Germania 161
HK - Hong Kong 122
UA - Ucraina 98
FR - Francia 94
SG - Singapore 73
FI - Finlandia 64
TR - Turchia 63
BG - Bulgaria 41
ID - Indonesia 18
IN - India 17
BE - Belgio 16
CA - Canada 13
RU - Federazione Russa 12
VN - Vietnam 10
IE - Irlanda 9
AU - Australia 8
CH - Svizzera 8
CZ - Repubblica Ceca 8
IR - Iran 7
MY - Malesia 7
LT - Lituania 6
BZ - Belize 5
ES - Italia 4
EU - Europa 3
GP - Guadalupe 3
MX - Messico 3
AT - Austria 2
BR - Brasile 2
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CR - Costa Rica 1
EC - Ecuador 1
IL - Israele 1
JP - Giappone 1
KR - Corea 1
KZ - Kazakistan 1
MA - Marocco 1
MM - Myanmar 1
MU - Mauritius 1
NL - Olanda 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
RS - Serbia 1
Totale 6.776
Salva come PNG Salva come JPEG
Città #
Southend 1.070
Fairfield 592
Woodbridge 458
Ashburn 352
Chandler 269
Houston 266
Seattle 240
Wilmington 216
Ann Arbor 206
Cambridge 203
Jacksonville 202
Dearborn 163
Nyköping 162
Beijing 129
Hong Kong 122
Modena 94
New York 76
San Diego 57
Singapore 44
Frankfurt am Main 42
Princeton 42
Sofia 41
Eugene 38
Helsinki 30
Izmir 29
Bremen 26
London 25
Milan 23
Bologna 20
Redwood City 17
Brussels 16
Falls Church 16
Nanjing 13
Boardman 12
Des Moines 12
Fremont 12
Jakarta 12
San Jose 12
Shanghai 12
Dong Ket 10
Dublin 9
Norwalk 9
Rho 9
Chicago 8
Hefei 8
Indiana 8
Kunming 8
Phoenix 8
Rome 8
San Giuliano Milanese 8
San Mateo 8
Uppsala 7
Dongguan 6
Hebei 6
Verona 6
Belize City 5
Melbourne 5
Padova 5
Reggio Emilia 5
Ardabil 4
Augusta 4
Carpi 4
Hounslow 4
Kilburn 4
Mirandola 4
Novate Milanese 4
Paris 4
Parma 4
Saint Petersburg 4
Stoneham 4
Zhengzhou 4
Abano Terme 3
Amritsar 3
Auburn Hills 3
Brno 3
Gainesville 3
Guangzhou 3
Jinan 3
Lavello 3
Leawood 3
Nanchang 3
New Delhi 3
Ottawa 3
Palangkaraya 3
Roncoferraro 3
Saint-Francois 3
Stockholm 3
Bangalore 2
Banjarmasin 2
Baotou 2
Beachwood 2
Budapest 2
Castelnuovo Rangone 2
Catanzaro 2
Charlottetown 2
Chiswick 2
Curno 2
Dietikon 2
Edinburgh 2
Grimma 2
Totale 5.639
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 516
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 308
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 244
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 242
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 241
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 239
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 202
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 199
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 195
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 195
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 186
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 184
A concise review of lenalidomide therapy for follicular lymphoma 183
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 182
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 177
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 172
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 172
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 159
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 159
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 156
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 151
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 148
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 148
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 144
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 141
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 140
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 140
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 139
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 138
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. 137
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 137
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 129
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 129
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 123
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 118
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 104
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 100
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 94
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 92
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 86
Totale 6.849
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.354 0 65 42 105 147 207 212 158 160 65 92 101
2020/20211.437 186 62 110 150 197 94 81 122 67 114 176 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/202573 66 7 0 0 0 0 0 0 0 0 0 0
Totale 6.849